Eisai’s Lenvima Will Face Off Against Nexavar In Thyroid Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Approved two months early, tyrosine kinase inhibitor’s labeling reflects 14.7-month progression-free survival improvement in patients with differentiated thyroid cancer, almost triple the benefit seen with Bayer/Amgen’s sorafenib.